Targeting Immune Checkpoints in Cancer Therapy
Author:
- 7 November 2017
- journal article
- viewpoint
- Published by American Medical Association (AMA) in JAMA
- Vol. 318 (17) , 1647-1648
Abstract
This Viewpoint reviews the development of immune checkpoint inhibitors as a new drug class for treating cancer, and discusses future directions including develoKeywords
This publication has 7 references indexed in Scilit:
- Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapyNature Reviews Cancer, 2016
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyNew England Journal of Medicine, 2015
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer TherapyCancer Cell, 2015
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996